OTCPK:VRTT

Stock Analysis Report

Executive Summary

Viatar CTC Solutions Inc., a biotechnology company, focuses on developing and marketing cancer molecular diagnostics and cancer therapy products in the United States.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Viatar CTC Solutions's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VRTT has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

VRTT

0.7%

US Biotechs

-1.1%

US Market


1 Year Return

n/a

VRTT

14.0%

US Biotechs

17.9%

US Market

Return vs Industry: Insufficient data to determine how VRTT performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how VRTT performed against the US Market.


Shareholder returns

VRTTIndustryMarket
7 Day0%0.7%-1.1%
30 Day0%5.6%1.4%
90 Day0%6.2%6.9%
1 Yearn/a14.9%14.0%20.3%17.9%
3 Year-65.0%-65.0%24.4%21.1%47.8%38.3%
5 Yearn/a3.8%-1.0%71.9%53.0%

Price Volatility Vs. Market

How volatile is Viatar CTC Solutions's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Viatar CTC Solutions undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Viatar CTC Solutions is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Viatar CTC Solutions has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of VRTT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Viatar CTC Solutions regulatory filings here.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Viatar CTC Solutions forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Viatar CTC Solutions has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Viatar CTC Solutions performed over the past 5 years?

23.7%

Historical Pharmaceuticals & Biotech annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Viatar CTC Solutions has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Viatar CTC Solutions's financial position?


In this section we usually analyse Viatar CTC Solutions's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Viatar CTC Solutions has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of VRTT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Viatar CTC Solutions's financial data was last updated here.
  • Explore more healthy companies in the Pharmaceuticals & Biotech industry.

Dividend

What is Viatar CTC Solutions's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VRTT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate VRTT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VRTT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VRTT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VRTT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average board tenure


CEO

Viatar CTC Solutions has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Ilan Reich
Founder & Director11.9yrsno datano data
David Tierney
Director3.6yrsno datano data
Jack Stover
Director3.4yrsno datano data
David Boral
Director3.6yrsno datano data

3.6yrs

Average Tenure

59.5yo

Average Age

Experienced Board: VRTT's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

Viatar CTC Solutions Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Viatar CTC Solutions Inc.
  • Ticker: VRTT
  • Exchange: OTCPK
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.365m
  • Shares outstanding: 19.50m
  • Website: https://www.viatarctcsolutions.com

Number of Employees


Location

  • Viatar CTC Solutions Inc.
  • 116 John Street
  • Suite 10
  • Lowell
  • Massachusetts
  • 1852
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VRTTOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJun 2015

Biography

Viatar CTC Solutions Inc., a biotechnology company, focuses on developing and marketing cancer molecular diagnostics and cancer therapy products in the United States. Its products include Viatar collection system for molecular analysis that collects and purifies circulating tumor cells (CTCs) for DNA sequencing and other genetic analysis technologies used primarily for research; and Viatar therapeutic oncopheresis system to remove CTCs from a patient’s blood as a new cancer therapy for metastatic disease. The company was formerly known as Vizio Medical Devices LLC and changed its name to Viatar CTC Solutions Inc. in February 2014. Viatar CTC Solutions Inc. was founded in 2007 and is headquartered in Lowell, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/30 00:30
End of Day Share Price2019/10/01 00:00
Earnings2016/09/30
Annual Earnings2015/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.